WO2001046194A2 - Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives - Google Patents
Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives Download PDFInfo
- Publication number
- WO2001046194A2 WO2001046194A2 PCT/EP2000/013001 EP0013001W WO0146194A2 WO 2001046194 A2 WO2001046194 A2 WO 2001046194A2 EP 0013001 W EP0013001 W EP 0013001W WO 0146194 A2 WO0146194 A2 WO 0146194A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- compound
- fluorine atoms
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Definitions
- This invention relates to a process for the preparation of pyrazolopyridazine derivatives and to intermediates for use therein.
- R° is halogen, d-ealkyl, Ci-ealkoxy, Ci-ealkoxy substituted by one or more fluorine atoms, or O(CH 2 ) n NR 4 R 5 ;
- R 1 and R 2 are independently selected from H, C-i-ealkyl, C ⁇ - 6 alkyl substituted by one or more fluorine atoms, C(O)H,
- Ci-ealkoxy substituted by one or more fluorine atoms O(CH 2 ) n CO 2 C ⁇ - 6 alkyl, O(CH 2 ) n SC 1 - 6 alkyl, (CH 2 ) n NR R 5 or
- R 3 is Chalky, or NH 2 ;
- R 4 and R 5 are independently selected from H, or C ⁇ - 6 alkyl or, together with the nitrogen atom to which they are attached, form a 4 - 8 membered saturated ring; and n is 1-4; are disclosed in international patent application publication no. WO99/12930, incorporated herein by reference.
- pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate or ester, or salt or solvate of such ester, of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
- salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable salts thereof.
- Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts formed with inorganic or organic acids, preferably inorganic acids, e.g. hydrochlorides, hydrobromides and sulphates.
- halogen is used to represent fluorine, chlorine, bromine or iodine.
- alkyl' as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.
- the compounds of formula (I) are potent and selective inhibitors of COX-2. They are of interest for use in human and veterinary medicine, particularly in the treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases.
- the present invention provides a particularly advantageous process of preparing compounds of formula (I), not hitherto specifically disclosed, which comprises oxidation of a corresponding dihydro-pyrazolopyridazine. Accordingly, in a first aspect, the instant invention provides a process for the preparation of a compound of formula (I) which comprises oxidising under conventional conditions a compound of formula (II)
- R° to R 3 are as defined for formula (I).
- the oxidation is effected in a solvent, such as a halogenated alkane (e.g. dichloromethane); at ambient to elevated temperature, such as from 20°C to reflux (e.g. at about 25 °C); and in the presence of a catalyst, such as activated carbon, or a transition metal catalyst (e.g. palladium on activated carbon).
- a catalyst such as activated carbon, or a transition metal catalyst (e.g. palladium on activated carbon).
- the catalyst may be replaced by an oxidising agent, such as a source of oxygen (e.g. air), or iodine.
- the process according to the invention is surprisingly advantageous, being easy to carry out and proceeding in good yield.
- the invention provides a process for preparing a compound of formula (I) where R° is at the 3- or 4-position of the phenyl ring, as defined in formula (I).
- the invention provides a process for preparing a compound of formula (I) where R 1 is at the 6-position of the pyridazine ring, as defined in formula (I).
- the invention provides a process for preparing a compound of formula (I) where R° is F, C ⁇ - 3 alkyl, C ⁇ - 3 alkoxy, C ⁇ alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) ⁇ - 3 NR 4 R 5 ; or, more preferably, R° is F, C ⁇ - 3 alkoxy or C ⁇ - 3 alkoxy substituted by one or more fluorine atoms.
- the invention provides a process for preparing a compound of formula (I) where R 1 is C ⁇ - alkylsulphonyl, C ⁇ - 4 alkoxy substituted by one or more fluorine atoms, 0(CH 2 ) ⁇ - 3 C0 2 C ⁇ ._,alkyl, (CH 2 ) ⁇ - 3 NR 4 R 5 , (CH 2 ) ⁇ - 3 SC ⁇ -*alkyl or C(O)NR 4 R 5 or, when R° is C ⁇ alkyl, d-ealkoxy, O(CH 2 ) ⁇ NR 4 R 5 , may also be H; or, more preferably, R 1 is substituted by one or more fluorine atoms or, when R° is C ⁇ - 6 alkyl,
- C ⁇ - 6 alkoxy, C ⁇ - 6 alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) n NR 4 R 5 , may also be H.
- the invention provides a process for preparing a compound of formula (I) where R 2 is H.
- the invention provides a process for preparing a compound of formula (I) where R 3 is methyl or NH 2 .
- the invention provides a process for preparing a compound of formula (I) where R 4 and R 5 are independently C ⁇ - 3 alkyl or, together with the nitrogen atom to which they are attached, form a 5 - 6 membered saturated ring.
- the invention provides a process for preparing a compound of f froirrmmuullaa ( ( ⁇ I) ⁇ n n i ics 11 _- 3, m mnorroe prroeffoerr ⁇ abhllvy/ 11 n orr 29.
- the invention provides a process for preparing one group of compounds of formula (I) (group A) wherein: R° is F, C ⁇ - 3 alkyl, C ⁇ - 3 alkoxy, C ⁇ - 3 alkoxy substituted by one or more fluorine atoms, or O(CH 2 ) n NR 4 R 5 ; R 1 is C ⁇ - 4 alkoxy substituted by one or more fluorine atoms,
- the invention provides a process for preparing another group of compounds (group A1) wherein R° is F, methyl, C ⁇ - 2 aikoxy, OCHF 2 , or O(CH 2 ) n NR 4 R 5 ; R is methylsulphonyl, OCHF 2 , O(CH 2 ) n C0 2 C ⁇ _ alkyl, O(CH 2 ) n SCH 3 , (CH 2 ) n NR 4 R 5 , (CH 2 ) n SCH 3 or C(O)NR 4 R 5 or, when R° is methyl, C ⁇ . 2 alkoxy, OCHF 2 , or O(CH 2 ) n N(CH 3 ) 2 , may also be H; R 2 is H; R 3 is methyl or
- R 4 and R 5 are both methyl or, together with the nitrogen atom to which they are attached, form a 5 - 6 membered saturated ring; and n is 1 - 2.
- the invention provides a process for preparing a compound of formula (I) within group (group A2) wherein R° is F, C ⁇ - 3 alkoxy or C ⁇ - 3 alkoxy substituted by one or more fluorine atoms; R 1 is C ⁇ - 4 alkoxy substituted by one or more fluorine atoms or, when R° C ⁇ - 3 alkoxy or C ⁇ - 3 alkoxy substituted by one or more fluorine atoms, may also be H; R 2 is H; and R 3 is methyl or NH 2 .
- the invention provides a process for preparing a compound of formula (I) within groups A, A1 and A2, wherein R° is preferably at the 3- or
- the invention provides a process for preparing the compound 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1 ,5-b]pyridazine and pharmaceutically acceptable derivatives thereof.
- the present invention provides a particularly advantageous process for the preparation of compounds of formula (II), as illustrated in Scheme 1 that follows.
- Suitable inorganic bases include alkali hydroxides (e.g. NaOH); suitable organic bases include amines (e.g. N,N,N,N-tetramethylethylened ⁇ am ⁇ ne). It will be appreciated by those skilled in the art that the imines of formula (III) prepared from the ethanones of formula (V) need not necessarily be isolated and may be employed in situ in the preparation of compounds of formula (II).
- Counterion X in the N-aminopyridazinium salts of formula (IV) is conveniently a halide (e.g. I ) or, more preferably, hexafluorophosphate (PF 6 ).
- N-Aminopyridazinium hexafluorophosphate salts of formula (IV) are novel and their use according to Scheme 1 is surprisingly advantageous.
- N-aminopyridazinium hexafluorophosphate salts of formula (IV) are easily prepared and enable the conversion of ethanones of formula (V) to compounds of formula (II) via imines of formula (III) to proceed easily and in high yield.
- the invention provides N-aminopyridazinium hexafluorophosphate salts of formula (IV) wherein R° to R 3 are as defined for formula (I) above, in particular N-aminopyridazinium hexafluorophosphate.
- the present invention encompasses all isomers of the compounds of formula (II) and pharmaceutically acceptable derivatives thereof, including all positional, geometric, tautomeric, optical and diastereomeric forms, and mixtures thereof (e.g. racemic mixtures).
- N-Aminopyridazinium halides of formula (IV) are either known compounds or may be prepared by literature methods such as those described in, for example, Y Kobayashi et al, Chem Pharm Bull, (1971), 19(10), 2106-15; T. Tsuchiya, J. Kurita and K. Takayama, Chem. Pharm. Bull. 28(9) 2676-2681 (1980); and K Novitskii et al, Khim Geterotskil Soedin, 1970 2, 57-62; all incorporated herein by reference.
- N-Aminopyridazinium hexafluorophosphates of formula (IV) may be prepared by reacting the corresponding N-aminopyridazinium sulphate with hexafluorophosphoric acid or a suitable salt thereof (e.g. potassium hexafluorophosphate or ammonium hexafluorophosphate).
- hexafluorophosphoric acid or a suitable salt thereof e.g. potassium hexafluorophosphate or ammonium hexafluorophosphate.
- the aforementioned sulphates may be prepared from pyridazine by conventional means.
- compounds of formula (I) are isolated following work-up in the form of the free base.
- Pharmaceutically acceptable acid addition salts of the compounds of formula (I) may be prepared using conventional means.
- Solvates e.g. hydrates of a compound of formula (I) may be formed during the work-up procedure of one of the aforementioned process steps.
- the required isomer may conveniently be separated using preparative high performance liquid chromatography (h.p.l.c).
- TMEDA N,N,N,N-tetramethylethyienediamine
- DCM dichloromethane
- TFA trfluoroacetic acid
- s singlet
- d doublet
- t triplet
- m multiplet
- Example 4 By using a 60%w/w aqueous solution of hexafluorophosphoric acid (15.2g), the title compound was obtained as a white crystalline solid (10.4g, 68.8% based on pyridazine) in the manner of Example 1 and was spectroscopically identical thereto.
- Example 4
- Example 5 A solution of 1-(4-ethoxyphenyl)-2-[4-(methylsulfonyl)phenyl]ethanone (0.5g) in DCM (10mL) was treated with triethylamine (0.22mL) followed by titanium tetrachloride (0.52mL). To the resultant deep red solution was added N-aminopyridazinium iodide 1 (0.26g) and the mixture was heated under reflux for 18 hours. The reaction mixture was cooled to about 20°C and treated dropwise with water (5mL). The organic phase was washed with sodium hydroxide solution (2N, 5mL), concentrated to dryness and a sample of the resulting crude solid analysed by HPLC-NMR. Ref: 1 Y Kobayashi et al, Chem Pharm Bull, (1971) 19(10), 2106-15 Column Inertsil ODS-2 20cm x 0.46cm (5 ⁇ M)
- the concentrate was further diluted with ethyl acetate (150mL), heated to 60°C, filtered through a pad of celite, and the celite filtercake washed with warm ethyl acetate (100mL).
- the combined filtrate and washes were heated to 60°C, washed with 2M sodium hydroxide (50mL), 20% aqueous sodium thiosulfate (2x50mL), water (2x50mL) and concentrated to 4 volumes by distillation at atmospheric pressure. The slurry was stirred overnight at ambient temperature and then at 5°C for 3.5 hours.
- the crude product was washed with DCM/iso-octane (1 :1 , 2 x 150mL) and iso-octane (400mL), dried, and then dissolved in acetone (1200mL). This solution was heated to about 50°C and treated with charcoal (19g) for about 1 hour before filtering. The charcoal was washed with hot acetone (750mL) and the combined filtrates and washings were concentrated by distillation to a residual volume of about 825mL. Further acetone (375ml) was added to the concentrate, which was concentrated again to a residual volume of about 825mL. Maintaining the temperature at about 50°C, water (450mL) was added over about 1 hour, causing the product to crystallise.
- Example 9 After cooling the slurry to about 0-5°C the product was isolated by filtration, washed with chilled acetone/water (1 :1 , 2 x 150mL), and dried in vacuo at 65°C to give the title compound as a pale yellow crystalline solid (63.6g, 68.6%), spectroscopically identical to the product of Example 7.
- Example 9
- Titanium tetrachloride (3.45mL) was added to a stirred mixture of 1-(4- ethoxyphenyl)-2-(4-methanesulfonyl-phenyl)-ethanone (10. Og), N-aminopyridazinium hexafluorophosphate (7.95g) in dichloromethane (150mL) at about 20°C.
- N-Methyl-pyrrolidinone (3.0mL) was added at about 20°C.
- TMEDA (6.7mL) was then added over a period of about 4 hours at about 20°C. After stirring the mixture for about 1 hour, a second portion of TMEDA (12.3mL) was added over about 20 minutes, and the reaction mixture was stirred at about 20°C for about 16 hours.
- Mass Spectroscopy (Micromass ZMD spectrometer)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26751/01A AU776777B2 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridazine derivatives |
IL15027400A IL150274A0 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridazine derivatives |
AT00990004T ATE299506T1 (en) | 1999-12-22 | 2000-12-20 | METHOD FOR PRODUCING PYRAZOLO(1,5-B)PYRIDAZINE DERIVATIVES |
US10/168,002 US6803463B2 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridine derivatives |
PL00356141A PL356141A1 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridazine derivatives |
EP00990004A EP1242424B1 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives |
MXPA02006132A MXPA02006132A (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridazine derivatives. |
JP2001547104A JP2003518121A (en) | 1999-12-22 | 2000-12-20 | Preparation of pyrazolopyridazine derivatives |
NZ519691A NZ519691A (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolo[1,5-B]pyridazine derivatives |
BR0016549-2A BR0016549A (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridazine derivatives |
KR1020027007988A KR20020062362A (en) | 1999-12-22 | 2000-12-20 | Process for the Preparation of Pyrazolopyridazine Derivatives |
HU0203407A HUP0203407A3 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolopyridazine derivatives |
DE60021286T DE60021286T2 (en) | 1999-12-22 | 2000-12-20 | PROCESS FOR PREPARING PYRAZOLO [1,5-B] PYRIDAZINE DERIVATIVES |
CA002395569A CA2395569A1 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives |
NO20023041A NO323412B1 (en) | 1999-12-22 | 2002-06-21 | Process for the preparation of pyrazolopyridazine derivatives and intermediates. |
HK02108757.4A HK1047586B (en) | 1999-12-22 | 2002-12-03 | Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930358.8A GB9930358D0 (en) | 1999-12-22 | 1999-12-22 | Process for the preparation of chemical compounds |
GB9930358.8 | 1999-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001046194A2 true WO2001046194A2 (en) | 2001-06-28 |
WO2001046194A3 WO2001046194A3 (en) | 2002-05-30 |
Family
ID=10866856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/013001 WO2001046194A2 (en) | 1999-12-22 | 2000-12-20 | Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives |
Country Status (22)
Country | Link |
---|---|
US (1) | US6803463B2 (en) |
EP (1) | EP1242424B1 (en) |
JP (1) | JP2003518121A (en) |
KR (1) | KR20020062362A (en) |
CN (1) | CN1197864C (en) |
AT (1) | ATE299506T1 (en) |
AU (1) | AU776777B2 (en) |
BR (1) | BR0016549A (en) |
CA (1) | CA2395569A1 (en) |
CZ (1) | CZ20022178A3 (en) |
DE (1) | DE60021286T2 (en) |
ES (1) | ES2243343T3 (en) |
GB (1) | GB9930358D0 (en) |
HK (1) | HK1047586B (en) |
HU (1) | HUP0203407A3 (en) |
IL (1) | IL150274A0 (en) |
MX (1) | MXPA02006132A (en) |
NO (1) | NO323412B1 (en) |
NZ (1) | NZ519691A (en) |
PL (1) | PL356141A1 (en) |
WO (1) | WO2001046194A2 (en) |
ZA (1) | ZA200204911B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004056394A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxo Group Limited | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain |
US7235560B2 (en) | 2002-08-19 | 2007-06-26 | Glaxo Group Limited | Pyrimidine derivative as selective COX-2 inhibitors |
US7446117B2 (en) | 2002-09-16 | 2008-11-04 | Glaxo Group Limited | Cox-2 inhibiting pyridine derivatives |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0021494D0 (en) * | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
GB0112810D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112802D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0227443D0 (en) * | 2002-11-25 | 2002-12-31 | Glaxo Group Ltd | Pyrimidine derivatives |
US7145762B2 (en) * | 2003-02-11 | 2006-12-05 | Taser International, Inc. | Systems and methods for immobilizing using plural energy stores |
GB0319037D0 (en) * | 2003-08-13 | 2003-09-17 | Glaxo Group Ltd | 7-Azaindole Derivatives |
DE102006040754B3 (en) * | 2006-08-31 | 2008-03-27 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Disc brake, in particular for a commercial vehicle |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031509A1 (en) * | 1995-04-04 | 1996-10-10 | Glaxo Group Limited | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES |
WO1999012930A1 (en) * | 1997-09-05 | 1999-03-18 | Glaxo Group Limited | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58134094A (en) * | 1982-02-02 | 1983-08-10 | Mitsubishi Paper Mills Ltd | 3-formyl-pyrazolo(1,5-b)pyridazine derivative and preparation thereof |
US5002941A (en) | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
US5155114A (en) | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
CA2060309A1 (en) | 1989-06-13 | 1990-12-14 | Alison M. Badger | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
EP0533837A4 (en) | 1990-06-12 | 1994-11-17 | Smithkline Beecham Corp | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases |
GB9015764D0 (en) | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
EP0833664A1 (en) | 1995-06-12 | 1998-04-08 | G.D. SEARLE & CO. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations |
US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
DE69635048T2 (en) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | MEDIUM, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR |
DE69915519T2 (en) * | 1999-02-27 | 2005-02-03 | Glaxo Group Ltd., Greenford | pyrazolopyridines |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
-
1999
- 1999-12-22 GB GBGB9930358.8A patent/GB9930358D0/en not_active Ceased
-
2000
- 2000-12-20 WO PCT/EP2000/013001 patent/WO2001046194A2/en active IP Right Grant
- 2000-12-20 PL PL00356141A patent/PL356141A1/en not_active Application Discontinuation
- 2000-12-20 EP EP00990004A patent/EP1242424B1/en not_active Expired - Lifetime
- 2000-12-20 AT AT00990004T patent/ATE299506T1/en not_active IP Right Cessation
- 2000-12-20 AU AU26751/01A patent/AU776777B2/en not_active Ceased
- 2000-12-20 HU HU0203407A patent/HUP0203407A3/en unknown
- 2000-12-20 MX MXPA02006132A patent/MXPA02006132A/en active IP Right Grant
- 2000-12-20 KR KR1020027007988A patent/KR20020062362A/en not_active Application Discontinuation
- 2000-12-20 CN CNB008176582A patent/CN1197864C/en not_active Expired - Fee Related
- 2000-12-20 US US10/168,002 patent/US6803463B2/en not_active Expired - Fee Related
- 2000-12-20 CZ CZ20022178A patent/CZ20022178A3/en unknown
- 2000-12-20 BR BR0016549-2A patent/BR0016549A/en not_active IP Right Cessation
- 2000-12-20 CA CA002395569A patent/CA2395569A1/en not_active Abandoned
- 2000-12-20 DE DE60021286T patent/DE60021286T2/en not_active Expired - Fee Related
- 2000-12-20 IL IL15027400A patent/IL150274A0/en unknown
- 2000-12-20 NZ NZ519691A patent/NZ519691A/en unknown
- 2000-12-20 ES ES00990004T patent/ES2243343T3/en not_active Expired - Lifetime
- 2000-12-20 JP JP2001547104A patent/JP2003518121A/en active Pending
-
2002
- 2002-06-19 ZA ZA200204911A patent/ZA200204911B/en unknown
- 2002-06-21 NO NO20023041A patent/NO323412B1/en unknown
- 2002-12-03 HK HK02108757.4A patent/HK1047586B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031509A1 (en) * | 1995-04-04 | 1996-10-10 | Glaxo Group Limited | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES |
WO1999012930A1 (en) * | 1997-09-05 | 1999-03-18 | Glaxo Group Limited | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors |
Non-Patent Citations (3)
Title |
---|
KATRITZKY, A.R.: "Comprehensive Heterocyclic Chemistry II, Vol. 8" 1996 , PERGAMON PRESS , OXFORD, GB XP002163745 page 362 * |
KATRITZKY, A.R.: "Comprehensive Heterocyclic Chemistry, Vol. 5" 1984 , PERGAMON PRESS , OXFORD, GB XP002163744 Scheme 101 page 339-340 * |
PATENT ABSTRACTS OF JAPAN vol. 007, no. 248 (C-193), 4 November 1983 (1983-11-04) & JP 58 134094 A (MITSUBISHI SEISHI KK), 10 August 1983 (1983-08-10) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235560B2 (en) | 2002-08-19 | 2007-06-26 | Glaxo Group Limited | Pyrimidine derivative as selective COX-2 inhibitors |
US7446117B2 (en) | 2002-09-16 | 2008-11-04 | Glaxo Group Limited | Cox-2 inhibiting pyridine derivatives |
WO2004056394A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxo Group Limited | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain |
JP2006512345A (en) * | 2002-12-20 | 2006-04-13 | グラクソ グループ リミテッド | Combination of vanilloid antagonist and NSAID for the treatment of pain |
US7390817B2 (en) | 2002-12-20 | 2008-06-24 | Glaxo Group Limited | Combinations of a vanilloid antagonist and an NSAID for the treatment of pain |
Also Published As
Publication number | Publication date |
---|---|
EP1242424B1 (en) | 2005-07-13 |
ATE299506T1 (en) | 2005-07-15 |
CA2395569A1 (en) | 2001-06-28 |
ES2243343T3 (en) | 2005-12-01 |
HK1047586B (en) | 2005-12-16 |
IL150274A0 (en) | 2002-12-01 |
AU776777B2 (en) | 2004-09-23 |
JP2003518121A (en) | 2003-06-03 |
PL356141A1 (en) | 2004-06-14 |
NO20023041L (en) | 2002-08-16 |
DE60021286D1 (en) | 2005-08-18 |
ZA200204911B (en) | 2004-02-13 |
NZ519691A (en) | 2004-06-25 |
AU2675101A (en) | 2001-07-03 |
DE60021286T2 (en) | 2005-12-29 |
EP1242424A2 (en) | 2002-09-25 |
US20030078267A1 (en) | 2003-04-24 |
KR20020062362A (en) | 2002-07-25 |
MXPA02006132A (en) | 2002-12-05 |
NO323412B1 (en) | 2007-04-30 |
NO20023041D0 (en) | 2002-06-21 |
WO2001046194A3 (en) | 2002-05-30 |
BR0016549A (en) | 2002-09-17 |
HUP0203407A3 (en) | 2004-12-28 |
US6803463B2 (en) | 2004-10-12 |
CN1197864C (en) | 2005-04-20 |
CZ20022178A3 (en) | 2003-02-12 |
HK1047586A1 (en) | 2003-02-28 |
CN1413215A (en) | 2003-04-23 |
HUP0203407A2 (en) | 2003-01-28 |
GB9930358D0 (en) | 2000-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1242424B1 (en) | Process for the preparation of pyrazolo[1,5-b]pyridazine derivatives | |
WO2014005443A1 (en) | Method for preparing selective anticoagulant ticagrelor and the intermediate thereof | |
US5939045A (en) | Organic bismuth derivatives for X-ray imaging | |
US20060052613A1 (en) | 1-alkyl-3-aminoindazoles | |
JPH10512874A (en) | Method for producing 2- (substituted benzoyl) -1,3-cyclohexanediones | |
WO1995017408A1 (en) | Synthesis of diaryl methanes | |
RU2315044C2 (en) | Method for preparing chiral 1,4-disubstituted piperazines | |
FI129733B (en) | Process for the preparation of arylsulfonylpropenenitriles | |
EP1000933B1 (en) | Trifluoro methylthiomethyl benzene derivatives and process for producing the same | |
JP3868534B2 (en) | Process for producing sulfonamide derivatives and intermediates | |
KR100302346B1 (en) | A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline | |
JPH0613477B2 (en) | 5-hydrazino-1H-pyrazole compound | |
WO2001083479A2 (en) | Process for the preparation of pyrazolopyridine derivatives | |
EP0294615B1 (en) | Cyclobutene-3,4-dione-intermediates and their use in the preparation of histamine h2-antagonists | |
KR930004794B1 (en) | Process for preparing 1-lower alkoxy-1-lower alkyl-3-substituted phenylurea and intermediate thereof and process for production of the intermediate | |
AU2002241271B2 (en) | Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate | |
JP4241975B2 (en) | Method for producing 2-sulfonylpyridine derivative | |
WO2002042261A2 (en) | PROCESS FOR PREPARING α-(3-ARYLTHIO)-ACETOPHENONES | |
AU8863498A (en) | Process for the preparation of 2-alkylthio benzoic acid derivatives | |
JP2003506312A (en) | Meta-nitrophenol derivative and method for producing the same | |
US4447604A (en) | Thiazolotriazine derivatives | |
JPH02134343A (en) | Preparation of cyclopentene, cyclopentane and cyclohexane derivative | |
KR20010040836A (en) | Processes and Intermediates Useful to Make Antifolates | |
CN115353514A (en) | Fluoro-pyridopyrimidone compound and synthetic method thereof | |
JPH0543535A (en) | Production of phenyl ether derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10168002 Country of ref document: US Ref document number: 26751/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 150274 Country of ref document: IL Ref document number: 2000990004 Country of ref document: EP Ref document number: 2395569 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/00826/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/04911 Country of ref document: ZA Ref document number: 200204911 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2001 547104 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/006132 Country of ref document: MX Ref document number: PV2002-2178 Country of ref document: CZ Ref document number: 519691 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027007988 Country of ref document: KR Ref document number: 008176582 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027007988 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000990004 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-2178 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 519691 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 519691 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 26751/01 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000990004 Country of ref document: EP |